Earnest Partners LLC cut its stake in Agilent Technologies Inc (NYSE:A) by 1.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 362,078 shares of the medical research company’s stock after selling 5,215 shares during the period. Earnest Partners LLC owned 0.11% of Agilent Technologies worth $22,391,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Quantitative Systematic Strategies LLC raised its holdings in shares of Agilent Technologies by 247.6% during the second quarter. Quantitative Systematic Strategies LLC now owns 23,818 shares of the medical research company’s stock worth $1,473,000 after purchasing an additional 16,966 shares during the period. California Public Employees Retirement System raised its holdings in shares of Agilent Technologies by 8.2% during the first quarter. California Public Employees Retirement System now owns 787,911 shares of the medical research company’s stock worth $52,711,000 after purchasing an additional 59,959 shares during the period. FIL Ltd acquired a new stake in shares of Agilent Technologies during the first quarter worth $15,596,000. Harvey Investment Co. LLC acquired a new stake in shares of Agilent Technologies during the second quarter worth $5,742,000. Finally, Employees Retirement System of Texas raised its holdings in shares of Agilent Technologies by 34.7% during the first quarter. Employees Retirement System of Texas now owns 136,000 shares of the medical research company’s stock worth $9,098,000 after purchasing an additional 35,000 shares during the period.
In related news, Director Boon Hwee Koh sold 6,931 shares of the stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $66.38, for a total value of $460,079.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of A opened at $67.36 on Friday. The stock has a market capitalization of $21.34 billion, a P/E ratio of 28.54, a P/E/G ratio of 2.30 and a beta of 1.35. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.62 and a quick ratio of 2.88. Agilent Technologies Inc has a 52-week low of $60.42 and a 52-week high of $75.00.
Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, August 14th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.04. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.20 billion. Agilent Technologies had a net margin of 6.20% and a return on equity of 18.61%. Agilent Technologies’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 EPS. equities research analysts expect that Agilent Technologies Inc will post 2.71 EPS for the current fiscal year.
A number of brokerages have weighed in on A. ValuEngine cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 18th. Deutsche Bank increased their target price on shares of Agilent Technologies from $77.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, August 15th. Morgan Stanley upped their price target on shares of Agilent Technologies from $83.00 to $84.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 15th. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price target for the company in a research report on Tuesday, August 7th. Finally, Cowen upgraded shares of Agilent Technologies from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 15th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $75.67.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Featured Story: Leveraged Buyout (LBO)
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.